← Back to Search

Omega-3 Fatty Acid

AlmgaPL for High Cholesterol

Phase 4
Waitlist Available
Led By Eneko Ganuza Taberna, PhD
Research Sponsored by Qualitas Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
New iwi/AlmegaPL subscribers.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to month 6
Awards & highlights

Study Summary

This trial will test whether Almega PL, an algae-based extract rich in EPA, can improve heart health indicators in iwi customers.

Eligible Conditions
  • High Cholesterol
  • Triglycerides
  • Omega-3 Fatty Acids
  • Eicosapentaenoic Acid

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Triglyceride change from baseline
Secondary outcome measures
Fasting glucose
HDL-cholesterol change from Baseline
HbA1c change from Baseline
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AlmgaPLExperimental Treatment1 Intervention
New consumers of iwi self-elected to start taking 2 capsules a day with 1000 mg of AlmegaPL, containing 250 mg of eicosapentaenoic acid (EPA), 150 mg polar lipids and 15 mg chlorophyll.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AlmegaPL (FDA NDIN # 826)
2022
Completed Phase 4
~250

Find a Location

Who is running the clinical trial?

Qualitas HealthLead Sponsor
Arizona State UniversityOTHER
283 Previous Clinical Trials
109,264 Total Patients Enrolled
Eneko Ganuza Taberna, PhDPrincipal InvestigatorQualitas Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
NutrientsJournal
Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-blind, Randomized, Placebo-controlled, Three-month Supplementation Study
Rao, Amanda, David Briskey, Jakob O Nalley, and Eneko Ganuza. 2020. “Omega-3 Eicosapentaenoic Acid (EPA) Rich Extract from the Microalga Nannochloropsis Decreases Cholesterol in Healthy Individuals: A Double-blind, Randomized, Placebo-controlled, Three-month Supplementation Study”. Nutrients. MDPI AG. doi:10.3390/nu12061869.
clinicaltrials.govStudy
AlmegaPL CV Health Open Label Study
2022. "AlmegaPL CV Health Open Label Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05267301.
~86 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top